CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cinclus Pharma Holding publ AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cinclus Pharma Holding publ AB
Kungsbron 1, Level 3, Elevator G
Phone: +46 8133310p:+46 8133310 STOCKHOLM, 111 22  Sweden Ticker: CINPHACINPHA
Business Summary
Cinclus Pharma Holding AB (publ) (Cinclus Pharma) is a Sweden-based research based biotech company developing small molecules for the treatment of gastric acid related diseases. The Company is developing linaprazan glurate, which is being developed for the treatment of severe gastroesophageal reflux disease (GERD). The Company's mission is to introduce products impacting standard of care for patients with gastric acid related diseases, underpinned by the superior P-CAB linaprazan glurate. Cinclus Pharma is in an intensive development phase, ramping up the organization and company structure to prepare for growth and the further development of linaprazan glurate. Cinclus Pharma owns the worldwide commercial rights for linaprazan glurate. Secured commercial rights are central in utilizing the process of launching the product in markets worldwide.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Stig L.Hansson 68 5/16/2022 5/16/2022
External Chief Executive Officer Sven C.Ahlberg 53 5/16/2022 5/16/2022
Interim Chief Financial Officer PatrikNorgren 63 12/8/2025 12/8/2025
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Cinclus Pharma Holding AB
CINPHA

General Information
Number of Employees: 21 (As of 12/31/2025)
Outstanding Shares: 47,392,219 (As of 12/31/2025)
Shareholders: 4,228
Stock Exchange: STO


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 27, 2026